Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808

Chien, David; Szardenings, Anna Katrin; Bahri, Shadfar; Walsh, Joseph C.; Mu, Fanrong; Xia, Chunfang; Shankle, William R.; Lerner, Alan J.; Su, Min‐Ying; Elizarov, Arkadij M.; Kolb, Hartmuth C.

doi:10.3233/jad-130098

Cited by 440 publications

(196 citation statements)

References 23 publications

Supporting

Mentioning

193

Contrasting

Order By: Relevance

“…Early imaging results with 18 F-T807, 18 F-T808 and 18 F-THK5105 are proving to be useful in confirming the presence of tauopathy in various clinical situations, including AD. [178][179][180] In a recent AD study, the magnitude of tau tracer signal correlated positively with the stage of disease and severity of cognitive impairment. 180 A third tau PET tracer, 11 C-PBB3, has been tested in healthy individuals and patients with AD, and may be able to detect non-AD conformations of tau.…”

Section: Fluid-based Biomarkersmentioning

confidence: 93%

Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions

et al. 2015

View full text Add to dashboard Cite

Section: Fluid-based Biomarkersmentioning

confidence: 93%

Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions

et al. 2015

View full text Add to dashboard Cite

“…Radiometabolites were measured in a subset of samples (4,8,15,30,60,90,130,170, and 210 min) by reversed-phase high-performance liquid chromatography, and plasma protein binding free fraction was measured by ultrafiltration (Centrifree; Millipore).…”

Section: Blood Sampling and Analysismentioning

confidence: 99%

Kinetic Modeling of the Tau PET Tracer ¹⁸F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects

Barret

Alagille

Sanabria³

et al. 2016

J Nucl Med

View full text Add to dashboard Cite

18 F-AV-1451 is currently the most widely used of several experimental tau PET tracers. The objective of this study was to evaluate 18 F-AV-1451 binding with full kinetic analysis using a metabolitecorrected arterial input function and to compare parameters derived from kinetic analysis with SUV ratio (SUVR) calculated over different imaging time intervals. Methods: 18 F-AV-1451 PET brain imaging was completed in 16 subjects: 4 young healthy volunteers (YHV), 4 aged healthy volunteers (AHV), and 8 Alzheimer disease (AD) subjects. Subjects were imaged for 3.5 h, with arterial blood samples obtained throughout. PET data were analyzed using plasma and reference tissue-based methods to estimate the distribution volume, binding potential (BP ND ), and SUVR. BP ND and SUVR were calculated using the cerebellar cortex as a reference region and were compared across the different methods and across the 3 groups (YHV, AHV, and AD). Results: AD demonstrated increased 18 F-AV-1451 retention compared with YHV and AHV based on both invasive and noninvasive analyses in cortical regions in which paired helical filament tau accumulation is expected in AD. A correlation of R 2 . 0.93 was found between BP ND (130 min) and SUVR-1 at all time intervals. Cortical SUVR curves reached a relative plateau around 1.0-1.2 for YHV and AHV by approximately 50 min, but increased in AD by up to approximately 20% at 110-130 min and approximately 30% at 160-180 min relative to 80-100 min. Distribution volume (130 min) was lower by 30%-35% in the YHV than AHV. Conclusion: Our data suggest that although 18 F-AV-1451 SUVR curves do not reach a plateau and are still increasing in AD, an SUVR calculated over an imaging window of 80-100 min (as currently used in clinical studies) provides estimates of paired helical filament tau burden in good correlation with BP ND , whereas SUVR sensitivity to regional cerebral blood changes needs further investigation.

show abstract

“…2). Brain PET images with 18 F-T808 in humans, however, show intense bone uptake in the skull due to defluorination, which may hamper visual image interpretation (19). Human 18 F-T807 PET results seem to be the most promising, although the reported data come from a limited sample of 6 subjects (20).…”

Section: Overview Of Tau Pet Tracers Under Developmentmentioning

confidence: 99%

Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers

Shah

Catafau

2014

J Nucl Med

View full text Add to dashboard Cite

Neurodegenerative diseases are characterized by progressive dysfunction and neuronal death, showing specific protein inclusions at autopsy. In vivo detection of these key proteins, namely amyloid-β, tau, α-synuclein, and trans-active response DNAbinding protein 43 kDa, is possible by means of molecular neuroimaging techniques, such as PET. The development of selective PET radiotracers targeting these proteins is critical for early and accurate diagnosis and for the successful development of disease-modifying therapies. Selective PET radiotracers for amyloid-β are already available, and potential tau tracers are emerging as new-generation biomarkers. An overview of the tau-PET radiotracer development scenario, focusing on tracers that are presently being examined in humans, is presented.

show abstract

Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808

Cited by 440 publications

References 23 publications

Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions

Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions

Kinetic Modeling of the Tau PET Tracer ¹⁸F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects

Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers

Contact Info

Product

Resources

About

Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808

Cited by 440 publications

References 23 publications

Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions

Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions

Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects

Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers

Contact Info

Product

Resources

About

Kinetic Modeling of the Tau PET Tracer ¹⁸F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects